PEGS Summit Korea
PEGS Korea

트랙 2

암 면역치료

9월 21일-22일

항CTLA-4 항체 및 항PD-1/항PD-L1 항체의 임상시험이 성공하고 규제기관의 승인을 얻으면서 면역 체크포인트 저해제에 대한 관심은 그 어느 때보다 높아지고 있습니다. 이와 같은 성과는 암 면역치료의 거대한 가능성을 나타내는 사례의 일부에 불과하다고 볼 수 있으며, 단독요법을 비롯한 다른 T세포 지향성 약제 및 보조자극 인자, 방사선요법 및 화학요법 등 기존의 치료법과 조합한 병용요법에 대한 기대도 커지고 있습니다.

CHI 는 성장세가 뚜렷한 바이오테크놀러지 기업이 집중된 한국에서 많은 연구자가 이 분야에 강한 관심을 보이고 있다는 점을 기반으로 암 면역치료에 초점을 맞춘 트랙을 제2회 PEGS Korea에서 개최합니다. 이 트랙에는 한국을 비롯한 세계 각국으로부터 다양한 기업의 인사가 참가할 전망이며, 면역 체크포인트 저해제의 현재 개발 상황과 향후 전망, T세포 양자면역치료의 엔지니어링 및 제조 문제 등에 대해 논의하고 현재 임상시험이 진행되고 있는 병용 면역치료의 전략 및 최신 정보 등도 소개됩니다.

아젠다 최종판

2016년 9월 21일(수)

13:00 등록

13:50 의장 개회사

Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Department of Biochemistry, University of Zurich


기조 강연

Philip Gotwals14:00 특정 표적에 대한 면역 시스템의 활성화에 의한 치료

Philip Gotwals, Ph.D., Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of Biomedical Research

Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T cell function (checkpoint inhibitors), engineered cell therapies, and innate immune stimulators such as oncolytic viruses are effective in a wide range of cancers. This presentation will illustrate therapeutic approaches to treating cancer with immune-based therapies using examples from the Novartis Immuno-oncology pipeline.

Patrick_Bauerle14:30 암치료를 위한 T세포 동원 항체:작용기서

Patrick A. Baeuerle, Ph.D., Managing Director, MPM Capital

CD19/CD3-bispecific antibody blinatumomab (Blincyto®) is approved in the US and EU for treatment of patients with relapsed/refractory B-ALL. Much still has to be learned on how such T cell-engaging antibodies can redirect any kind of T cell for target cell lysis. My presentation will cover all necessary steps including bispecific binding, T cell activation, serial lysis, T cell expansion, tumor eradication, bystander effect, epitope spreading and the impact of immune escape mechanisms.


15:00 스폰서 제공 프레젠테이션(발표자 모집)

15:30 전시회장 휴식시간, 포스터 발표 관람


면역 체크포인트 저해제

16:10 종양괴사인자 리간드 슈퍼패밀리(TNFSF) 멤버 LIGHT에 의한 체크포인트 저해제에 대한 저항 극복

Jieyi Wang, Ph.D., Senior Principal Scientist, Oncology Biologics, AbbVie

Checkpoint blockade therapies with anti-PD-1/PD-L1 antibodies induce durable responses in cancer patients but fail to work in the majority of patients. Sufficient T cell infiltration in tumor tissues is a prerequisite for the response to checkpoint blockade, and targeting cancer with tumor necrosis factor superfamily member LIGHT leads to the production of chemokines that recruit massive numbers of T cells. Thus LIGHT can create a T cell-inflamed microenvironment and overcome tumor resistance to checkpoint blockade.

16:40 동물 모델과 임상시험 간 갭의 극복:인비트로 어세이 활용에 의한 암 면역치료 개발의 가속

Sofie Pattijn, CTO, ImmunXperts

With the new wave of candidate cancer therapies acting mainly on the immune system via immune checkpoint blockade and other pathways, the demand for in vitro characterization of these molecules has significantly increased. This presentation will give a technical overview of a series of in vitro assays using human primary cells used for the characterization of new leads. Also, the major benefits, limitations and challenges will be discussed.

17:10 면역 체크포인트 저해제:독성과 유해사례 감시

Amer Alghabban, MSc Pharmacol., Vice President, GxP Quality Assurance, Compliance and Training, Research & Development, Karyopharm Therapeutics, Inc.

The presentation aims to answer the question of why the need for monitoring toxicities/adverse events? What are the unique mechanisms and unique side effects? What are immune-related adverse events (irAEs)? How to manage immune-related adverse events (irAEs)?

17:40 둘째날 종료

17:40 쇼트코스 등록

18:00 디너 쇼트코스*:항체 구축물의 엔지니어링

*별도 참가 등록 필요

 

2016년 9월 22일(목)

8:00 커피

8:30 의장 발언

Jin-San Yoo, Ph.D., CEO, President and Founder, PharmAbcine


양자 T세포요법

8:40 암 면역치료 - 구상의 실현

Weikang Tao, Ph.D., Vice President & CEO, R&D Center, Jiangsu Hengrui Medicine Co., Ltd.

Recent breakthroughs in treating different types of advanced-stage malignancies by harnessing self-immunity against neoplastic cells showed a great promise of immunotherapy for cancer treatment. Various strategies have been employed to unleash, enhance or elicit anticancer immune reactions, which include T-cell checkpoint blockade, engineered T cells, BiTE, modified cytokines and cancer vaccines. This presentation will review recent progress in cancer immunotherapy and discuss some immunotherapeutic agents discovered and developed at Hengrui Medicine.

9:10 조혈모세포(HSC)분화를 기반으로 한 암의 NK세포요법

Inpyo Choi, Ph.D., Director, Immunotherapy Convergence Center, Korea Research Institute of Bioscience & Biotechnology

We have developed the efficient methods to expand and differentiate mature NK cells in vitro. Using these mature NK cells differentiated from HSC, anti-tumor activity for in vivo tumor models was tested. In vivo tests showed that mature NK cells eradicated tumors efficiently. In clinical trials, NK cells given after haploidentical HCT decreased relapse of leukemia and enhanced donor cell engraftment, but did not cause GVHD.

9:40 고형 종양에 대응하는 신규 범용 키메라 항원 수용체 발현 T세포(CAR-T) 시스템

Bong-Kook Ko, Ph.D., Deputy Director, Antibody Therapeutic Research Center, AbClon, Inc.

We have developed a novel universal CAR-T system to improve safety and manufacturing process with anti-hapten CAR-T and hapten-conjugated targeting agent. The hapten is physiologically absent, pharmacologically inert and non-toxic, and high affinity anti-hapten antibody enables CAR-T cell to kill cancer cells efficiently. This system provides several advantages like micro-dosing approach, removal of CAR-T with hapten-conjugated toxin, multiple targeting with different hapten-conjugated agents, and simple manufacturing of CAR-T.

10:10 전시회장 휴식시간, 포스터 발표 관람

10:40 강화된 면역학적 활성을 실현하는 항PD-L1 항체 기반 이중특이성/이중기능성 항체의 엔지니어링

Zhenping Zhu, M.D., Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corporation, LLC

11:10 암치료용 MOGAM의 이중특이성항체 동원 T세포

Hyung-Kwon (Harry) Lim, Ph.D., Antibody Engineering, Mogam Biotechnology Institute

This presentation describes the challenges and opportunities of recent work of Mogam for the bispecific antibodies. The design concept of the bispecific antibodies engaging between T cells and tumor associated antigens and its characterization will be shared in terms of manufacturability and functionality. In addition, the performance about cell killing activities and T cell activation against several antigen specific cancer cells in the various experimental settings will be demonstrated.

11:40 B세포 림프종에 대응하는 CD19 항체 표적화 키메라 항원 수용체 발현 T세포요법

Keiya Ozawa, M.D., Ph.D., Director, IMSUT Hospital, Director, Center for Gene & Cell Therapy, Professor, Division of Genetic Therapeutics, University of Tokyo

12:10 스폰서 제공 프레젠테이션(발표자 모집)

12:40 전시회장 오찬회, 포스터 발표 관람(스폰서 모집)


암치료 및 염증 치료 분야의 항체 및 이중특이성항체

13:45 의장 발언

Young Woo Park, Ph.D., CEO, Y Biologics

13:50 새로운 이중특이성항체 기술을 이용한 차세대 생물제제의 개발

Chengbin Wu, Ph.D., CEO, EpimAb Biotherapeutics

Targeting multiple disease pathways or mediators becomes an important therapeutic strategy in a number of indications, such as inflammation and cancer. Here we present a novel bispecific technology that can efficiently combine the functions of two mAbs into one bi-functional Ig-like molecule.

14:20 Tanibirumab의 임상 개발과 차세대 이중특이성항체의 진보

Jin-San Yoo, Ph.D., CEO, President and Founder, PharmAbcine

Tanibirumab is an anti-human VEGFR2 (KDR) neutralizing fully human IgG1 with murine/monkey cross species cross neutralizing reactivity so that all kinds of in vivo studies are possible. Tanibirumab Phase I data has shown that 60% of patients showed stable disease due to Tanibirumab and no common side effects like hypertension and hemorrhage/bleeding. Currently, Tanibirumab is in Phase IIa with recurrent GBM multi-center trial in Australia. PMC-001, a bispecific antibody neutralizing both VEGF-VEGFR2 and ANG-TIE2 pathways, is in development like PMC-201, neutralizing both VEGF-VEGFR2 and Notch-DLL4 pathways.

14:50 이중특이성항체 기술을 이용한 차세대 항체 치료제

Tomoyuki Igawa, Ph.D., Head of Biologics Discovery, Research Division, Chugai Pharmaceutical Co., Ltd.

We have established a bispecific antibody technology named ART-Ig to enable large scale manufacturing of the bispecific antibody. In this session, three examples of next generation bispecific antibody therapeutics will be presented: bispecific antibody against factor IXa and factor X for the treatment of hemophilia A, bispecific antibody against tumor specific antigen and T cell surface marker CD3 for cancer immunotherapy, and biparatopic antibody with pH-dependent binding property for elimination of soluble antigen from plasma.

15:20 Y Biologics의 면역치료 프로그램:개발과 진전

Young Woo Park, Ph.D., CEO, Y Biologics

Y Biologics is a leading RND company with excellency in platform technologies, such as human antibody library screening, human receptor library screening and antibody optimization. Based on expertise, Y Biologics is developing first-in-class antibody drugs and bi-specific antibodies in auto-inflammatory and immune-oncology area. New cancer targeting antibody and unique immune check point antibodies, which are in early research stage, will be introduced.

15:50 종양 파괴 바이러스 면역치료제 Pexa-Vec과 암면역 병용요법에서의 지위

Paul Youm, J.D., Legal Counsel, SillaJen, Inc.

Pexa-Vec is an oncolytic virus immunotherapy designed to selectively target and attack cancer cells, currently undergoing a global Phase III trial in liver cancer (HCC). Oncolytic viruses are positioning themselves uniquely in the field as a promising agent in different immunotherapy combination regimens, especially with immune checkpoint inhibitors in various cancers.

16:20 컨퍼런스 폐막




* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.


Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English



기업 스폰서

 MaxCyte

기업 지원 스폰서


GeneScript

스폰서 조직


theAntibodySocietyLogo

Antibody Society Korea



Arrow Right Col미디어 파트너


 

트랙 1
Arrow Right Col 단백질 엔지니어링과 항체 엔지니어링


트랙 2
Arrow Right Col 암 면역치료




Catalog
국제컨퍼런스
Giievent
메일링 서비스
메일링 서비스